CompletedNCT00449397
Quetiapine dose for first-episode psychosis
About this title
Read the official source — NCT00449397Medication studyAges 15–25AustraliaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 15 years to 25 years.
- Listed locations
- MelbourneSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 150
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia
- Age range
- From 15 Years to 25 Years
- Official registry ID
- NCT00449397
- Official title
Show the full official title
A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Melbourne
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine Fumarate.
Who was this study for?
Listed age limits: 15 years to 25 years.
